Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.
This video will offer guidance on initiation protocols for venetoclax treatment in adult patients with chronic lymphocytic leukemia (CLL).
On June 3rd, Johnson & Johnson announced updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of patients with r
According to data presented at ASCO 2023 on June 3rd, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the first-ever results from the Phase 1b RedirecTT-1 study of teclistam
Phase 1 clinical trial results demonstrate that in patients with nasopharyngeal carcinoma, EGFR-mutated non-small cell lung cancer, and other advanced soli
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->